Prucalopride is rapidly absorbed (Cmax attained 2-3 hours after single 2 mg oral dose) and is extensively distributed.
In vitro data indicate that prucalopride has a low interaction potential, and therapeutic concentrations of prucalopride are not expected to affect the CYP-mediated metabolism of co-medicated medicinal products [REF].